PuraCath is targeting the $19 Billion hospital acquired infection (HAI) industry. HAIs result from airborne and touch contamination of various catheters including vascular access, urinary, respiratory, and others. Currently, nurses have to manually scrub the hub of catheters for 15 seconds-2 minutes with alcohol or use expensive, disposable alcohol caps that have to stay on for 60 seconds. Compliance rates to current disinfection protocols is lower than 10%.
PuraCath has a platform of proprietary, smart, ultraviolet (UV) light devices that is able to get 99.99% disinfection on microorganisms that cause hospital acquired infections in less than 1 second of UV. This data has been validated in outside third party laboratories and published. PuraCath is also able to extract electronic health record (EHR) data and merge with its own data on disinfection time points in order to give hospitals a depiction of where they can enhance their staffing protocols and improve compliance.
PuraCath intends to monetize on the above, FireflyTM, product by having an internal sales force of 35-40 individuals and working with Group Purchasing Organizations, like Premier, to sell to the appropriate call points in hospitals nationwide. PuraCath has worked on its business plan extensively with veterans in the field.
PuraCath already has 1 FDA 510(k) clearance on a peritoneal dialysis UV device that is undergoing Chinese FDA clearance and will be commercialized overseas in the coming year. PuraCath's HAI device for hospitals is expected to receive FDA 510(k) clearance by the end of 2020. PuraCath has been published in the top AARP journal that is distributed to over 50 million seniors and has raised over $4.6MM in competitive non-dilutive financing from the National Science Foundation, National Institute of Health, and Department of Defense.